JORGE MANCILLA: Open Payments
NPI 1013665926 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,588 in 116 payments from 10 companies in 2025. Trend: 2023 $2,375 · 2024 $2,211 · 2025 $2,588
Food & beverage: $2,365Education: $223
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 20 | $567 |
| E.R. Squibb & Sons, L.L.C. | 11 | $312 |
| Neurocrine BioSciences, Inc. | 16 | $311 |
| Janssen Pharmaceuticals, Inc | 5 | $289 |
| Otsuka America Pharmaceutical, Inc. | 19 | $262 |
| Alkermes, Inc. | 10 | $199 |
| Lundbeck LLC | 8 | $195 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $193 |
| ABBVIE INC. | 13 | $160 |
| Axsome Therapeutics, Inc. | 5 | $100 |
Products named: REXULTI, COBENFY, INGREZZA, CAPLYTA, AUSTEDO XR, VRAYLAR, UZEDY, INVEGA SUSTENNA.
Industry payments across TX — which companies pay providers there.
